This website is intended for healthcare professionals only

Trending Topic

BADBIR Zenas Yiu psoriasis treatment real world
7 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

At the BAD 2026 meeting, new analyses from BADBIR highlighted the value of real-world evidence in answering clinically important questions in psoriasis care. The data explored serious infection risk across systemic treatments, the potential benefits of using biologics earlier in the treatment pathway, and risk factors for incident and recurrent erythrodermic psoriasis. Together, these findings demonstrate how registry data can complement clinical trial evidence by providing insights from routine clinical practice and helping to inform more personalized treatment decisions.

Cantharidin solution (0.7%) drug-device combination and its use in molluscum contagiosum: James Del Rosso

9 mins
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jan 10th 2024

Molluscum contagiosum, a common skin infection caused by a poxvirus (molluscum contagiosum virus), usually resulting in benign, mild skin disease characterized by lesions appearing anywhere on the body. In this interview, Dr. James Del Rosso (JDR Dermatology Research, Las Vegas, Nevada, USA, and President-Elect American Acne & Rosacea Society) shares insights into molluscum contagiosum, and addresses the current unmet needs in its treatment. Dr. Del Rosso also provides an in-depth look at the cantharidin solution (0.7%) drug-device combination, discussing its role and effectiveness in treating this condition.

Watch the expert perspective interview with Dr James Del Rosso on the efficacy and safety findings from CAMP-1 and CAMP-2 and cantharidin solution (0.7%) FDA approval.

Questions:

  1. Could you tell us a little about molluscum contagiosum and the unmet needs in its treatment?
  2. Could you describe the cantharidin solution (0.7%) drug-device combination?

Disclosures: James Del Rosso is a consultant and speaker for Verrica pharmaceuticals.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup